U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Medlife Pharmacy and Compounding, Inc. - 607417 - 11/29/2021
  1. Warning Letters

CLOSEOUT LETTER

Medlife Pharmacy and Compounding, Inc. MARCS-CMS 607417 —

Delivery Method:
VIA EMAIL CONFIRMED DELIVERY
Product:
Drugs
Recipient:
Recipient Name
Shar Eshraghi, Pharm.D.
Medlife Pharmacy and Compounding, Inc.

6644 Irvine Center Dr.
Irvine, CA 92618
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

Dear Dr. Eshraghi:

The U.S. Food and Drug Administration has completed an evaluation of your corrective actions in response to our warning letter (Ref CMS 607417) dated April 24, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and the FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top